<DOC>
	<DOCNO>NCT00659503</DOCNO>
	<brief_summary>The primary objective placebo-controlled EEU study determine time onset action ciclesonide , apply nasal spray ( 200 mg , daily ) patient SAR .</brief_summary>
	<brief_title>Study Using Environmental Exposure Unit ( EEU ) Assess Onset Action Ciclesonide , Applied Nasal Spray Treatment Seasonal Allergic Rhinitis ( BY9010/M1-407 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>1 . Written inform consent sign date subject conduct study related procedure . 2 . Male female patient 18 year old . 3 . General good health , free concomitant condition treatment , judgment investigator , could interfere study conduct , influence interpretation study observations/results , put patient increase risk trial . 4 . A history SAR short ragweed pollen minimum two year immediately precede study entry ( i.e. , 2003 2004 pollen season ) . In investigator 's judgment , SAR two year period must sufficient severity would expect require treatment ragweed season . 5 . A demonstrated sensitivity short ragweed pollen know induce SAR standard skin prick test . A positive test define wheal diameter least 3 mm large diluent ( negative ) control wheal skin prick test . Documentation positive result 12 month prior Screening Visit ( B0 ) acceptable . 6 . Female childbearing potential currently use continue use medically reliable method contraception entire study duration ( e.g . oral , injectable , transcutaneous implantable contraceptive intrauterine device doublebarrier protection ) . Females sexually active must agree use doublebarrier protection become sexually active course study . Women childbearing potential , less 1 year postmenopausal , require negative urine pregnancy test Screening Visit ( B0 ) well prior initiation treatment Treatment Visit ( T0 ) .Female subject consider nonchildbearing potential require urine pregnancy test least one follow apply : Before menarche ; More one year postmenopausal ; Had hysterectomy ; Had bilateral ovariectomy salpingectomy tubal ligation ; Have congenital sterility . 7 . Capable understanding requirement , risk , benefit study participation , , judge investigator , capable give informed consent , comply study requirement ( visit , record keep , etc ) , suitable participate , provide conscientious cooperation duration study possess characteristic suitable undertake study . 8 . Willingness undergo minimum one ( 1 ) maximum five ( 5 ) priming session short ragweed pollen EEU . 1 . Pregnancy , nursing , donation gamete ( ova sperm ) vitro fertilization study period plan become pregnant donate gamete ( ova sperm ) vitro fertilization 30 day follow study period . Females unwilling employ appropriate contraceptive measure ensure pregnancy occur study exclude . 2 . Have clinically significant physical finding nasal anatomical deformity cause great 50 % obstruction base upon clinical estimate investigator , include nasal polyp , septal defect clinically significant respiratory tract malformation , recent nasal biopsy , nasal trauma , nasal surgery atrophic rhinitis rhinitis medicamentosa ( within last 60 day prior Screening Visit B0 ) . 3 . Participation investigational drug trial within 30 day precede Screening Visit ( B0 ) thereafter . 4 . Known hypersensitivity corticosteroid excipients formulation . 5 . History severe respiratory infection disorder [ include , limited bronchitis , pneumonia , chronic sinusitis , influenza , severe acute respiratory syndrome ( SARS ) ] within 14 day precede Screening Visit ( B0 ) thereafter . 6 . History alcohol drug abuse within precede two year Screening Visit ( B0 ) . 7 . History positive test HIV , hepatitis B hepatitis C. 8 . Active asthma require treatment inhale systemic corticosteroid and/or routine use bagonists controller drug ( e.g . theophylline , leukotriene antagonist ) ; intermittent use ( less equal 3 us per week ) inhale shortacting bagonists acceptable . 9 . Use prohibit concomitant medication within prescribe ( per protocol ) exclusion period ( refer Section 6.3 protocol ) . 10 . Use antibiotic therapy acute condition within 14 day prior Screening Visit ( B0 ) thereafter . Low dos antibiotic take prophylaxis permitted therapy start prior Screening Visit ( B0 ) AND expect continue Baseline Period ( B0 T0 Visit ) Treatment Visit ( T0 ) . 11 . Initiation immunotherapy study period dose escalation study period . However , initiation immunotherapy 90 day prior Screening Visit ( B0 ) AND use stable ( maintenance ) dose ( 28 day prior Screening Visit ( B0 ) ) may consider inclusion provide immunotherapy injection receive within 48 hour prior ragweed pollen exposure visit . 12 . Previous participation intranasal ciclesonide study . 13 . Nonvaccinated exposure active infection , chickenpox measles within 21 day precede Screening Visit ( B0 ) . 14 . Exposure systemic corticosteroid indication , chronic intermittent ( e.g. , arthritis ) , past 60 day Screening Visit ( B0 ) , presence underlying condition reasonably expect require treatment corticosteroid course study . 15 . Use topical corticosteroid concentration excess 1 % hydrocortisone dermatological condition within 30 day prior Screening Visit ( B0 ) , presence underlying condition reasonably expect require treatment preparation course study ( B0 T0 Visit , visit inclusive ) . Hydrocortisone less equal 1 % concentration cover less equal 10 % total body surface without occlusion acceptable . 16 . History epilepsy seizure ( exclude febrile seizure ) . 17 . History coronary artery disease , uncontrolled hypertension , clinically significant cardiovascular disease . 18 . History malignancy ( exclude basal cell carcinoma ) . 19 . Have follow condition judge investigator clinically significant and/or affect subject 's ability participate clinical trial : Impaired hepatic function include alcohol relate liver disease cirrhosis ; History ocular disturbance e.g . glaucoma posterior subcapsular cataract ; Any systemic infection ; Hematological , renal , endocrine ( except control diabetes mellitus postmenopausal symptom hypothyroidism ) ; Gastrointestinal disease ; A current neuropsychiatric condition without drug therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Seasonal Allergic Rhinitis</keyword>
	<keyword>Ciclesonide</keyword>
	<keyword>Hay Fever</keyword>
	<keyword>SAR</keyword>
</DOC>